期刊文献+

NPM1突变基因调控K562白血病细胞侵袭表型的相关机制

Potential Role of Nucleophosmin (NPM1) Gene Mutations in K562 Leukemia Cell Invasion Phenotype
原文传递
导出
摘要 目的探讨CXCR4、Angs在NPM1突变参与调控的白血病细胞浸润转移中的作用,以期进一步明确NPM1突变在白血病浸润转移中的调控机制。方法通过基因转染构建稳定表达NPM1突变蛋白的K562白血病细胞株(K562-mA)。qRT—PCR检测各组细胞CXCR4、Ang-1/2的mRNA表达水平;Western免疫印迹和流式细胞仪分别检测细胞CXCR4总蛋白和膜蛋白的表达。结果建立了稳定表达NPM突变基因的K562-mA细胞株。与未处理组和空载体转染组相比,K562-mA细胞CXCR4的mRNA和蛋白表达水平显著增高;Ang-1mRNA表达水平明显降低、Ang-2mRNA表达水平明显增高。结论CXCR4、Ang-1/2可能在MPM1突变调控白血病细胞的浸润转移中发挥重要作用。 Objective To investigate the role of CXCR4 and Angs in the invasion phenotype in vitro of leukemic cells with NPM1 mutations, and further study the effect of NPM1 mutations on leukemia infiltration. Methods The pEGFPC1-NPMI-mA plasmid vector was transfected into K562 cells. The cells stably expressing NPMI-mA protein were established, named as K562-mA. The ex- pressions of CXCR4 and Ang-1/2 mRNA were assayed by quantitative Real-Time PCR (qRT-PCR). The expression of CXCR4 protein was assayed by Western blot and flow cytometry. Results Com- pared with control groups, CXCR4 mRNA and protein expression levels were significantly increased in K562-mA group. The expression of Ang-1 mRNA was markedly decreased, whereas Ang-2 mRNA expression was increased in K562-mA group. Conclusion CXCR4 and Ang-1/2 may play important roles in the invasion phenotype of leukemic cells with NPM1 mutations in vitro.
出处 《医学分子生物学杂志》 CAS CSCD 2011年第4期294-298,共5页 Journal of Medical Molecular Biology
基金 国家自然科学基金面上项目(No.30872418),重庆市科委自然科学基金(No.CSTC,2010BB5363)
关键词 白血病 核仁磷酸蛋白 基因突变 趋化因子受体4 血管生成素 leukemia nucleophosmin gene mutations chemokine receptor 4 angiopoietins
  • 相关文献

参考文献12

  • 1FALINI B, MECUCCI C,TIACCI E, et al. Cytoplasmic nucleophos- min in acute myelogenous leukemia with a normal karyotype[ J]. N Engl J Med,2005,352 ( 3 ) :254-266.
  • 2MEANI N, ALCALAY M. Role of nucleophosmin in acute myeloid leukemia[ J ]. Expert Rev Anticancer Ther, 2009,9 ( 9 ) : 1253- 1294.
  • 3邵会媛,苗宗玉,覃凤娴,陈先春,谭诗,钟梁,张伶.NPM1突变基因表达抑制K562白血病细胞体外增殖和侵袭[J].中国生物工程杂志,2010,30(11):6-10. 被引量:2
  • 4FURUSATO B, MOHAMED A, UHLEN M, et al. CXCR4 and cancer[ J]. Pathol Int,2010,60(7):497-505.
  • 5FIGUEROA-VEGA N, DIAZ A, ADRADOS M, et al. The associa- tion of the angiopoietin/Tie-2 system with the development of me- tastasis and leukocyte migration in neuroendocrine tumors[ J]. Endoer Relat Cancer,2010,17 (4) : 897-908.
  • 6DEN BESTEN W,KUO M L,WILLIAMS R T,et al. Myeloid leu- kemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein[ J]. Cell Cycle,2005 ,4 ( 11 ) :1593-1598.
  • 7BONETTI P, DAVOLI T, SIRONI C, et al. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through 17bw7 gamma [ J ]. J Cell Biol,2008,182 ( 1 ) : 19-26.
  • 8CHENG K,GRISENDI S,CLOHESSY J G,et al. The leukemia-as- sociated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions : Arf inactivation and induction of cellular se- nescence [ J ]. Oncogene,2007,26 ( 53 ) : 7391-7400.
  • 9ZHANG W, NAVENOT J M, FRILOT N M, et al. Association of nucleophosmin negatively regulates CXCR4-mediated G protein ac- tivation and chemotaxis [ J ]. Mol Pharmacol, 2007,72 ( 5 ) : 1310- 1321.
  • 10OELSCHLAEGEL U, MOHR B, SCHAICH M, et al. HLA-DRneg patients without acute promyelocytic leukemia show distinct immu-nophenotypic, genetic, molecular, and cytomorphologic characteris- tics compared to acute promyelocytic leukemia [ J ]. Cytom B Clin Cytom,2009,76(5) :321-327.

二级参考文献20

  • 1Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1 ; molecular basis and clinical implications. Leukemia, 2009, 23 ( 10 ) : 1731- 1743.
  • 2Meani N, Alcalay M. Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther, 2009, 9 ( 9 ) : 1283- 1294.
  • 3Zhang Y, Zhang M, Yang L, et al. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leukemia Research, 2007, 31 ( 1 ) : 109-111.
  • 4Piccaluga P P, Sabattini E, Bacci F, et al. Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. Leukemia, 2009, 23 (7) : 1370- 1371.
  • 5Cheng K, Grisendi S, Clohessy J G, et al. The leukemiaassociated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene, 2007, 26(53):7391-7400.
  • 6den Besten W, Kuo M L, Williams R T, et al. Myeloid Leukemia-Associated Nucleophosmin Mutants Perturb p53- Dependent and Independent Activities of the Arf Tumor Suppressor Protein. Cell Cycle, 2005, 4( 11 ) : 1593-1598.
  • 7Bonetti P, Davoli T, Sironi C, et al. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7γ. J Cell Biol, 2008, 182(1) : 19-26.
  • 8Falini B, Nicoletti I, Martelli M F, et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin ( NPMc + AML) : biologic and clinical features. Blood, 2007, 109 ( 3 ) : 874-885.
  • 9Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3- ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood, 2009, 113 (21) : 5250-5253.
  • 10Falini B, Mecucci C, Tiacci E,et al. Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. N Engl J Med, 2005, 352(3) : 254- 266.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部